{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:45:40Z","timestamp":1793303140900,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,10,7]],"date-time":"2015-10-07T00:00:00Z","timestamp":1444176000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,10,7]],"date-time":"2015-10-07T00:00:00Z","timestamp":1444176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"NCATS\/NIH","award":["UL1 TR000445"],"award-info":[{"award-number":["UL1 TR000445"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32HL007411T32"],"award-info":[{"award-number":["5T32HL007411T32"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s11239-015-1285-4","type":"journal-article","created":{"date-parts":[[2015,10,7]],"date-time":"2015-10-07T10:26:30Z","timestamp":1444213590000},"page":"656-662","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of the F2R IVS-14A\/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention"],"prefix":"10.1007","volume":"41","author":[{"given":"Eitan A.","family":"Friedman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Texeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Delaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Weeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Donald R.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab","family":"Kasasbeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanna","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Frank E.","family":"Harrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh C.","family":"Denny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi E.","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan M.","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Cleator","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,7]]},"reference":[{"key":"1285_CR1","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","volume":"62","author":"US Tantry","year":"2013","unstructured":"Tantry US, Bonello L, Aradi D et al (2013) Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62:2261\u20132273","journal-title":"J Am Coll Cardiol"},{"key":"1285_CR2","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","volume":"51","author":"D Trenk","year":"2008","unstructured":"Trenk D, Hochholzer W, Fromm MF et al (2008) Cytochrome P450 2C19 681G\u00a0>\u00a0A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51:1925\u20131934","journal-title":"J Am Coll Cardiol"},{"key":"1285_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/FPC.0b013e328333dafe","volume":"20","author":"A Harmsze","year":"2010","unstructured":"Harmsze A, van Werkum JW, Bouman HJ et al (2010) Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenet Genomics 20:18\u201325","journal-title":"Pharmacogenet Genomics"},{"key":"1285_CR4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1056\/NEJMoa0808227","volume":"360","author":"T Simon","year":"2009","unstructured":"Simon T, Verstuyft C, Mary-Krause M et al (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360:363\u2013375","journal-title":"N Engl J Med"},{"key":"1285_CR5","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","volume":"367","author":"JP Collet","year":"2012","unstructured":"Collet JP, Cuisset T, Range G et al (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367:2100\u20132109","journal-title":"N Engl J Med"},{"key":"1285_CR6","doi-asserted-by":"crossref","unstructured":"Bray PF (2007) Platelet hyperreactivity: predictive and intrinsic properties. Hematol Oncol Clin North Am 21:633\u2013645, v\u2013vi","DOI":"10.1016\/j.hoc.2007.06.002"},{"key":"1285_CR7","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1111\/j.1538-7836.2005.01377.x","volume":"3","author":"SR Coughlin","year":"2005","unstructured":"Coughlin SR (2005) Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 3:1800\u20131814","journal-title":"J Thromb Haemost"},{"key":"1285_CR8","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1161\/CIRCULATIONAHA.105.574830","volume":"114","author":"AJ Leger","year":"2006","unstructured":"Leger AJ, Covic L, Kuliopulos A (2006) Protease-activated receptors in cardiovascular diseases. Circulation 114:1070\u20131077","journal-title":"Circulation"},{"key":"1285_CR9","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1046\/j.1365-2141.1997.4973300.x","volume":"99","author":"D Lasne","year":"1997","unstructured":"Lasne D, Krenn M, Pingault V et al (1997) Interdonor variability of platelet response to thrombin receptor activation: influence of PlA2 polymorphism. Br J Haematol 99:801\u2013807","journal-title":"Br J Haematol"},{"key":"1285_CR10","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1182\/blood-2002-07-2149","volume":"101","author":"A Dupont","year":"2003","unstructured":"Dupont A, Fontana P, Bachelot-Loza C et al (2003) An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN. Blood 101:1833\u20131840","journal-title":"Blood"},{"key":"1285_CR11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1080\/00207230500120294","volume":"16","author":"SM Smith","year":"2005","unstructured":"Smith SM, Judge HM, Peters G et al (2005) PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy. Platelets 16:340\u2013345","journal-title":"Platelets"},{"key":"1285_CR12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/j.1538-7836.2009.03709.x","volume":"8","author":"D Sibbing","year":"2010","unstructured":"Sibbing D, Schulz S, Braun S et al (2010) Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 8:250\u2013256","journal-title":"J Thromb Haemost"},{"key":"1285_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.4244\/51","volume":"5","author":"T Cuisset","year":"2009","unstructured":"Cuisset T, Cayla G, Frere C et al (2009) Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 5:325\u2013329","journal-title":"EuroIntervention"},{"key":"1285_CR14","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1016\/j.jacc.2010.12.047","volume":"57","author":"G Campo","year":"2011","unstructured":"Campo G, Parrinello G, Ferraresi P et al (2011) Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 57:2474\u20132483","journal-title":"J Am Coll Cardiol"},{"key":"1285_CR15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.amjcard.2011.08.034","volume":"109","author":"G Parodi","year":"2012","unstructured":"Parodi G, Bellandi B, Venditti F et al (2012) Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. Am J Cardiol 109:214\u2013218","journal-title":"Am J Cardiol"},{"key":"1285_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/clpt.2011.221","volume":"91","author":"JT Delaney","year":"2012","unstructured":"Delaney JT, Ramirez AH, Bowton E et al (2012) Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther 91:257\u2013263","journal-title":"Clin Pharmacol Ther"},{"key":"1285_CR17","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/pds.2109","volume":"20","author":"A Cunningham","year":"2011","unstructured":"Cunningham A, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray WA (2011) An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf 20:560\u2013566","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1285_CR18","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL et al (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123:2736\u20132747","journal-title":"Circulation"},{"key":"1285_CR19","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.jcin.2012.05.010","volume":"5","author":"SV Rao","year":"2012","unstructured":"Rao SV, Dai D, Subherwal S et al (2012) Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients. JACC Cardiovasc Interv 5:958\u2013965","journal-title":"JACC Cardiovasc Interv"},{"key":"1285_CR20","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1161\/CIRCULATIONAHA.111.060871","volume":"125","author":"G Ndrepepa","year":"2012","unstructured":"Ndrepepa G, Schuster T, Hadamitzky M et al (2012) Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation 125:1424\u20131431","journal-title":"Circulation"},{"key":"1285_CR21","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","volume":"108","author":"JS Hulot","year":"2006","unstructured":"Hulot JS, Bura A, Villard E et al (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244\u20132247","journal-title":"Blood"},{"key":"1285_CR22","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa0809171","volume":"360","author":"JL Mega","year":"2009","unstructured":"Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354\u2013362","journal-title":"N Engl J Med"},{"key":"1285_CR23","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jama.2009.1232","volume":"302","author":"AR Shuldiner","year":"2009","unstructured":"Shuldiner AR, O\u2019Connell JR, Bliden KP et al (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849\u2013857","journal-title":"JAMA"},{"key":"1285_CR24","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","volume":"382","author":"GW Stone","year":"2013","unstructured":"Stone GW, Witzenbichler B, Weisz G et al (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382:614\u2013623","journal-title":"Lancet"},{"key":"1285_CR25","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jacc.2012.11.040","volume":"61","author":"AL Frelinger 3rd","year":"2013","unstructured":"Frelinger AL 3rd, Bhatt DL, Lee RD et al (2013) Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol 61:872\u2013879","journal-title":"J Am Coll Cardiol"},{"key":"1285_CR26","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.1016\/S0735-1097(12)60010-2","volume":"59","author":"MJ Price","year":"2012","unstructured":"Price MJ, Carfson AR, Murray SS et al (2012) First pharmacogenomic analysis using whole exome sequencing to identify novel genetic determinants of clopidogrel response variability: results of the Genotype Information and Functional Testing (GIFT) Exome Study. J Am Coll Cardiol 59:E9","journal-title":"J Am Coll Cardiol"},{"key":"1285_CR27","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1056\/NEJMp0806848","volume":"361","author":"DL Bhatt","year":"2009","unstructured":"Bhatt DL (2009) Prasugrel in clinical practice. N Engl J Med 361:940\u2013942","journal-title":"N Engl J Med"},{"key":"1285_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2217\/bmm.11.6","volume":"5","author":"IB Menown","year":"2011","unstructured":"Menown IB (2011) Aspirin, P2Y12 blockers, cilostazol, PAR-1 blockers and emerging antiplatelet therapies: can biomarkers guide clinical development and practice? Biomark Med 5:1\u20133","journal-title":"Biomark Med"},{"key":"1285_CR29","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1001\/jama.2013.1556","volume":"309","author":"AK Chhatriwalla","year":"2013","unstructured":"Chhatriwalla AK, Amin AP, Kennedy KF et al (2013) Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. JAMA 309:1022\u20131029","journal-title":"JAMA"},{"key":"1285_CR30","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/jama.2011.290","volume":"305","author":"MJ Price","year":"2011","unstructured":"Price MJ, Berger PB, Teirstein PS et al (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:1097\u20131105","journal-title":"JAMA"},{"key":"1285_CR31","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1160\/TH13-07-0624","volume":"111","author":"RF Storey","year":"2014","unstructured":"Storey RF, Kotha J, Smyth SS et al (2014) Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. Thromb Haemost 111:883\u2013891","journal-title":"Thromb Haemost"},{"key":"1285_CR32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1124\/jpet.114.215616","volume":"351","author":"JH Cleator","year":"2014","unstructured":"Cleator JH, Duvernay MT, Holinstat M et al (2014) Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects. J Pharmacol Exp Ther 351:33\u201343","journal-title":"J Pharmacol Exp Ther"},{"key":"1285_CR33","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/09537100400005634","volume":"16","author":"MW Behan","year":"2005","unstructured":"Behan MW, Fox SC, Heptinstall S, Storey RF (2005) Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes. Platelets 16:73\u201380","journal-title":"Platelets"},{"key":"1285_CR34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1109719","volume":"366","author":"P Tricoci","year":"2012","unstructured":"Tricoci P, Huang Z, Held C et al (2012) Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 366:20\u201333","journal-title":"N Engl J Med"},{"key":"1285_CR35","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","volume":"366","author":"DA Morrow","year":"2012","unstructured":"Morrow DA, Braunwald E, Bonaca MP et al (2012) Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366:1404\u20131413","journal-title":"N Engl J Med"},{"key":"1285_CR36","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S0140-6736(12)61269-0","volume":"380","author":"BM Scirica","year":"2012","unstructured":"Scirica BM, Bonaca MP, Braunwald E et al (2012) Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial. Lancet 380:1317\u20131324","journal-title":"Lancet"},{"key":"1285_CR37","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.114.013774","volume":"131","author":"MA Cavender","year":"2015","unstructured":"Cavender MA, Scirica BM, Bonaca MP et al (2015) Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. Circulation 131:1047\u20131053","journal-title":"Circulation"},{"key":"1285_CR38","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1016\/j.jacc.2014.09.037","volume":"64","author":"MP Bonaca","year":"2014","unstructured":"Bonaca MP, Scirica BM, Braunwald E et al (2014) Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2 degrees P-TIMI 50 trial. J Am Coll Cardiol 64:2309\u20132317","journal-title":"J Am Coll Cardiol"},{"key":"1285_CR39","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.2217\/pgs.14.153","volume":"15","author":"VK Kawai","year":"2014","unstructured":"Kawai VK, Cunningham A, Vear SI et al (2014) Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics 15:1973\u20131983","journal-title":"Pharmacogenomics"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-015-1285-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-015-1285-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-015-1285-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-015-1285-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T07:57:09Z","timestamp":1589702229000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-015-1285-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,7]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["1285"],"URL":"https:\/\/doi.org\/10.1007\/s11239-015-1285-4","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,7]]},"assertion":[{"value":"7 October 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}